lerdelimumab
Sign in to saveLerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.
It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition.
Excerpted from Wikipedia’s “lerdelimumab” article, available under the CC BY-SA 4.0 licence.